Loading...

Island Pharmaceuticals Limited

ILA.AXASX
Healthcare
Biotechnology
A$0.19
A$0.02(11.76%)

Island Pharmaceuticals Limited (ILA.AX) Company Profile & Overview

Explore Island Pharmaceuticals Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Island Pharmaceuticals Limited (ILA.AX) Company Profile & Overview

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.

SectorHealthcare
IndustryBiotechnology
CEODavid Charles Foster

Contact Information

61 3 7036 7675
697 Burke Road, Camberwell, VIC, 3124

Company Facts

IPO DateApr 13, 2021
CountryAU
Actively Trading

Frequently Asked Questions

;